The Bilgicer Group focuses on both understanding the basic dynamic principles of multivalent biomolecular interactions, as well as design of multivalent therapeutic and diagnostic molecules which will deliver novel solutions to complex diseases (e.g. cancer, autoimmune diseases, and allergies.)
NewsView all news
Media MentionsMore mentions
April 19, 2023
As Başar Bilgiçer co-author of the study explained, the reality is that “in the case of peanut allergy, there is no pathogen, just peanut proteins.”
February 13, 2023
“These new findings suggest that cHBI has the potential to be an effective preventative for peanut-specific allergic responses in patients,” said co-senior author Basar Bilgicer, Ph.D.
February 10, 2023
Professor Basar Bilgicer and his students have been hard at work on this project. It's one he's been invested in since 2008 and it's not a program that could've been rushed.
Originally published at news.nd.edu.